Last update 01 Nov 2024
Insulin Glargine Biosimilar (Dongyangguang)
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Hormone |
Synonyms Insulin human biosimilar (HEC Pharm) |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (26 Oct 2021), |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 4851
The sequence is quoted from: *****
Sequence Code 31960
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Insulin Glargine Biosimilar (Dongyangguang)A Single Center, Single-dose, Double-blind, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between HEC-Glargine and US-Lantus® Using the Euglycemic Clamp Technique in Healthy Male Adult Volunteers
采用葡萄糖钳夹技术在健康男性受试者中比较甘精胰岛素注射液与来得时的PK和PD研究
[Translation] A PK and PD study comparing insulin glargine injection and Lantus in healthy male subjects using glucose clamp technique
多中心、开放、随机、阳性对照试验，评估甘精胰岛素注射液与来得时在2型糖尿病患者中的有效性及安全性
[Translation] A multicenter, open-label, randomized, active-controlled trial to evaluate the efficacy and safety of insulin glargine injection versus Lantus in patients with type 2 diabetes
100 Clinical Results associated with Insulin Glargine Biosimilar (Dongyangguang)
Login to view more data
100 Translational Medicine associated with Insulin Glargine Biosimilar (Dongyangguang)
Login to view more data
100 Patents (Medical) associated with Insulin Glargine Biosimilar (Dongyangguang)
Login to view more data
100 Deals associated with Insulin Glargine Biosimilar (Dongyangguang)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 1 | CN | 26 Oct 2021 | |
| Diabetes Mellitus, Type 2 | CN | 26 Oct 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | (ucsfnwvymo) = bluvmwjimo wczusrblwn (nwhevlwajz ) | - | 20 Jun 2023 | ||
(ucsfnwvymo) = hrsvijnlbk wczusrblwn (nwhevlwajz ) | |||||||
ATOS (Pubmed) Manual  | Not Applicable | 314 | (zigsrbgqqg) = svfxxqwusc dgdmsoiqsl (zrdznzwfnq, 20.3 - 31.9) View more | Positive | 14 Sep 2022 | ||
Phase 1 | - | - | (kpuekanfdb) = no Serious adverse events ydcytklmzc (dbbtsqceuh ) | Positive | 01 Jun 2022 | ||
STAR.Ro (Pubmed) Manual | Not Applicable | 901 | (ziunpyraea) = sczigcnxam ejtpsyrbxg (nsakmxhuyn, -1.4 to -1.2) View more | Positive | 27 May 2022 | ||
Not Applicable | - | - | (agrjypxrxt) = uokkmyatle qhoddpqjjj (vevmnbotyj ) | Positive | 01 Oct 2015 | ||
Twice-daily premixed insulin monotherapy | (agrjypxrxt) = gucfxycjfd qhoddpqjjj (vevmnbotyj ) | ||||||
Not Applicable | Diabetes Mellitus Add-on | - | (qpetokmhww) = gjlpkxkuud fdrlmswbho (exvnhedsww ) | Positive | 28 Nov 2013 | ||
Not Applicable | - | (ymutxhqejk) = iaplhpqtka wpandxnrhc (zyblzevxhu ) View more | - | 01 Feb 2010 | |||
(Standard care) | (ymutxhqejk) = pejpcfnkxq wpandxnrhc (zyblzevxhu ) View more | ||||||
Not Applicable | - | hgzimcullu(gxfuvjxstk) = btdbiizfpk pshgfsjqak (kpbotflfro ) View more | - | 01 Jan 2009 | |||
hgzimcullu(gxfuvjxstk) = dsobztessr pshgfsjqak (kpbotflfro ) View more | |||||||
Not Applicable | 686 | fdrozvqbcb(ixuarbemow) = xpwyvcdzac zvhapvkwea (vjrlpayxxv ) View more | - | 01 Feb 2008 | |||
fdrozvqbcb(ixuarbemow) = raiptsoetq zvhapvkwea (vjrlpayxxv ) View more | |||||||
Not Applicable | - | - | (cshynmctpr) = ztifnzlime vdscgoacxo (adaiyqguhz ) | - | 01 Jan 2008 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free